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Abstract
Growing populations and ageing demographics lead to an 
increased burden of ischaemic heart disease and related cardio-
vascular interventions, resulting in pressure on healthcare sys-
tems. Although the healthcare system in Turkey has undergone 
comprehensive remodelling over the last decade, there are many 
challenges to overcome, including better reimbursement for car-
diovascular interventions, standardisation of interventional cardio-
logy services and research-related activities. In this manuscript, 
we present an overview of coronary and structural heart interven-
tions in Turkey, as well as providing information on current reim-
bursement policies and the healthcare system.
Demographics and organisation
Turkey is located at the crossroads between Europe and Asia and 
had over 78,740,000 inhabitants in December 2015, making it the 
third most populous country in Europe. Compared to the previous 
year, Turkey has seen a rise of 1,045,000 in the population.
Interventional procedures are performed in 341 catheterisa-
tion laboratories, 142 of which are in private hospitals. Twenty-
four percent of catheterisation laboratories are located in the city 
of Istanbul and 10% in the city of Ankara, with populations of 
around 15 and 5 million, respectively.
Our interventional working group, the Turkish Society 
of Cardiology-Association of Percutaneous Cardiovascular 
Interventions (TSC-APCI) (http://www.tkdgirisimsel.org/en) was 
founded 25 years ago. The main undertakings of the association 
include organising training activities in a wide range of cardiovas-
cular interventions in order to help increase the level of knowledge 
and skill set of the members. This will not only standardise cardio-
vascular interventions but also raise the quality of their practice. 
This is extremely important, especially since cardiology subspe-
cialities are not officially recognised in Turkey, leaving a com-
bination of local facilities, demands and personal interests to 
drive one’s ability/decision to practise as an interventionalist and 











organised by the TSC-APCI. Finally, although work is ongoing 
to create one, currently there is no structured national registry 
for percutaneous interventions in Turkey. The data below were 
extracted as being simply the total number of procedures from the 
National Insurance Institution.
The healthcare sector in Turkey has undergone comprehen-
sive remodelling in the last decade and recent investments have 
raised the quality of the country’s overall healthcare service. Such 
advancements have encouraged the use of technology and have 
helped expand the availability of procedures all over the country. 
In addition, the country’s social security system has seen a major 
transformation, which has greatly improved its efficiency. The evo-
lution of healthcare was constructed around the basis of unifying 
the control of different social security funds into a single institu-
tion. Under the “Universal Health Insurance” system, all residents 
registered with the Social Security Institution can now receive 
medical treatment, free of charge, in any Ministry of Health (MoH) 
or university hospital. The service also applies to most private hos-
pitals, whereby residents can receive medical services with consid-
erably discounted additional surcharges. Access to these services 
in private institutions is crucial: whilst MoH hospitals represent 
the larger proportion of the medical system, over the last decade 
Turkey has seen a significant rise in the number of private hospi-
tals that have increasingly helped to alleviate the growing demands 
on the healthcare service. The state also pays health premiums for 
the portion of the population classified as “low income” holding 
a green card. Furthermore, Universal Health Insurance now covers 
all residents under 25 years of age and has also been expanded to 
stateless persons and refugees. Such amendments have resulted in 
a more expansive healthcare system which has allowed the delivery 
of services in a fair and justifiable manner.
Data from 2015 reveal that 40.3% of the total number of deaths 
in Turkey were attributed to circulatory diseases, making them the 
leading cause of mortality. Ischaemic heart disease represented 
40.5% of these deaths related to circulatory disease. Furthermore, 
between 2012 and 2030, the number of deaths from cardiovascu-
lar disease is expected to rise at a rate of 27.8% per year. Such a 
progression in diseases poses a great financial burden that leads to 
strict reimbursement policies for the interventions.
Coronary interventions
Naturally, these policies differ between coronary and structural 
diseases. Coronary cases are usually reimbursed as packages. For 
example, the hospital is paid around 150 US dollars for diagnostic 
coronary angiography, regardless of whether it is a private or gov-
ernment-run hospital. A PCI case is roughly 400 US dollars, while 
balloons are refunded separately. Although stents are also reim-
bursed separately, drug-eluting stents are only reimbursed if their 
size is 3.0 mm or under. Bioresorbable scaffolds are not reim-
bursed. At present, the amount paid for intravascular ultrasound 
catheters is around 60% of their sale price, leading to consider-
able underutilisation of the technology. Similarly, fractional flow 
reserve (FFR) guidewires are also underutilised because they were 
not completely reimbursed until recently. An additional obstacle 
interventionalists face is the limited reimbursement of adjunc-
tive devices for complex procedures, such as microcatheters that 
are used for chronic total occlusions. Even the most complicated 
procedures are subject to packages, resulting in reluctance on 
the part of many interventionalists to perform these procedures, 
as most of the equipment easily exceeds the reimbursed amount. 
Table 1 shows some of the numbers of procedures over recent 
years. Peripheral interventions, including carotid stenting, are also 
increasingly being performed by the cardiologists. These proce-
dures are subject to more flexible reimbursement policies.
In Turkey, each year, in excess of 100,000 patients are admitted 
with an ST-segment elevated myocardial infarction. Prior to the onset 
of the Stent for Life (SFL) project, reperfusion was mainly achieved 
via thrombolysis and in 2010 only 8% of patients with acute STEMI 
had access to primary PCI1. As of 2009, Turkey joined the SFL pro-
ject and, at the start, 18 pilot cities were included around the coun-
try. The positive effects of this project can be seen in the growing 
number of primary PCIs: the cities with pilot studies running have 
been able to achieve a 90% rate of PCI, as well as a mean door-
to-balloon time of 54±43 minutes. Although the number of cities 
participating in the SFL project is increasing, there are various chal-
lenges that are yet to be overcome, including the shortage of staff.
Structural heart interventions
Percutaneous treatment of congenital diseases, including patent 
foramen ovale, are reimbursed completely in the form of pack-
ages, with any devices used reimbursed separately. On the other 
hand, transcatheter aortic valve implantation (TAVI) procedures 
are only reimbursed in teaching or step 3 university hospitals, for 
a selected group of high-risk patients. In Turkey, TAVI procedures 
cost five times more than aortic valve surgery, which is the main 
reason for the restricted use of this technology. Presently, percuta-
neous mitral valve repair procedures are not reimbursed (Table 2). 
Reimbursement for left atrial appendix closure and annuloplasty 
Table 1. Number of coronary cases over recent years in Turkey.
2010 2011 2012 2013 2014 2015
CAG n.a. n.a. 232,000 268,000 300,000 328,000
PCI n.a. n.a. 74,000 80,000 91,000 105,000
IVUS n.a. n.a. 491 1,072 1,017 405










devices is pending: these are expected to receive reimbursement 
soon. Therefore, currently, a small number of these latter procedures 
are performed based on private insurance or out-of-pocket payments.
Conclusion
Despite all the recent changes in healthcare and interventional 
cardiology in Turkey, many challenges have yet to be overcome. 
First, further developments in reimbursement policies are essential 
in order to keep up with innovations in interventional cardiology. 
As an association, we should encourage and negotiate with the 
MoH for these improvements. Secondly, increasing the research 
activities in which TSC-APCI is involved is an ongoing goal for 
the team. This involves building national registries, initiating or 
sponsoring multicentre trials, as well as participating in multina-
tional registries or studies.
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Table 2. Total number of some other cardiovascular procedures.
2010 2011 2012 2013 2014 2015
ASD/PFO closure n.a n.a 1,843 1,729 1,832 1,888
PMBV n.a n.a 638 623 751 688
PMVR n.a n.a 12 42 90 49
IABP n.a n.a 712 779 700 902
ASA n.a n.a 69 24 45 44
TAVI n.a n.a 149 225 434 609
ASA: alcohol septal ablation; ASD: atrial septal defect; IABP: intra-aortic balloon pump; n.a.: not available; PFO: patent foramen ovale; 
PMBV: percutaneous mitral balloon valvuloplasty; PMVR: percutaneous mitral valve repair; TAVI: transcatheter aortic valve implantation
